Leap Therapeutics, Inc. - LPTX Income before deduction of interest, taxes and amortization

Graphic logo of Leap Therapeutics Inc (LPTX)

Leap Therapeutics, Inc. (LPTX) is developing cancer immunotherapy through strategic partnerships to improve patient survival rates. The EBITDA_Co trend clearly demonstrates the current financial standing, where the metric value stands at . The business relies on grants as there are no sales. High clinical trial costs create a liquidity deficit, forcing the company to constantly raise external capital.

Profit before payment of interest, taxes and amortization: Leap Therapeutics, Inc. (LPTX) for 07/04/2022 - 11/16/2026

Leap Therapeutics Inc - analytical breakdowns and key metrics (LPTX)

- market value and analyst target forecast:
Analysis of all company metrics:Leap Therapeutics - LPTX
Mass-produced product of Leap Therapeutics

The market assesses the potential of Leap Therapeutics, Inc. (LPTX) through the lens of intellectual property for DKN-01 antibodies, which solidify the company's dominance in the immuno-oncology segment. By analyzing the annual EBITDA, an investor sees the net cash balance from operating activities excluding depreciation and taxes, allowing for an objective assessment of current business efficiency and the stability of its financial foundation.

Competitors of Leap Therapeutics, Inc. (LPTX)

ImmunityBio (IBRX) - Profit before interest, taxes and amortization|IMCR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization JANX (Janux Therapeutics, Inc.)|RCUS: Operating profit EBITDA|ZYME - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization tangotx.com|Operating profit before deduction of amortization iovance.com (IOVA)|Profit before payment of interest, taxes and amortization Immatics NV (IMTX)|Operating profit before deduction of amortization Xencor Corp XNCR|Compass Therapeutics Inc - Operating profit before deduction of amortization|Operating profit EBITDA Replimune Inc. REPL|LYEL - Profit before payment of interest, taxes and amortization|IPHA (innate-pharma.com) - Operating profit before amortization|pyxisoncology.com (PYXS) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Compugen Ltd. (CGEN)|Operating profit before deduction of amortization IOBT|STRO - Operating profit before depreciation charges|Operating profit before deduction of amortization INKT (MiNK)|Company profit before taxes, interest and amortization HOWL|Operating profit EBITDA IMMX (Immix Biopharma, Inc.)|Income before deduction of interest, taxes and amortization ALXO|CUE - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization PDS Biotechnology Corporation|Sonnet BioTherapeutics Holdings Inc. (SONN) - Profit before payment of interest, taxes and amortization|MAIA Biotechnology - Income before deduction of interest, taxes and amortization|LIMN (liminatuspharma.com) - Operating profit EBITDA|Operating profit EBITDA lavatherapeutics.com|Profit before payment of interest, taxes and amortization NextCure (NXTC)|INTS: Profit before deduction of interest, taxes, depreciation and amortization|Sensei Biotherapeutics, Inc. - Operating profit before deduction of amortization|Theriva Biologics (TOVX) - Profit before interest, taxes and amortization|gritstonebio.com - Operating profit EBITDA|KA (Kineta) - Operating profit before amortization|NEXI: Operating profit EBITDA|Turnstone Biologics Corporation (TSBX) - Operating profit EBITDA|VCNX (vaccinex.com) - Operating profit EBITDA|HARP: Income before deduction of interest, taxes and amortization